

**Fluoride & Bone Damage: Published Data**  
*Compiled by Michael Connett*  
*January 2004*

1. Bone damage in relation to Water Fluoride Content

TABLE 1: Bone/Teeth Effects Associated with Water Fluoride Content

2. Bone damage in relation to Daily Fluoride Dose

TABLE 2: Bone Effects Associated with Daily Doses of Fluoride

3. Bone damage in relation to Serum Fluoride Content

TABLE 3a: Average Serum Fluoride Levels Reported in Human Skeletal Fluorosis

TABLE 3b: Serum Fluoride Levels Causing Damage to Mineralized Tissues in Rats

TABLE 3c: Upper Serum Fluoride Levels Reported in Humans Living in  $\leq 1.9$  ppm areas

4. Bone damage in relation to Bone Fluoride Content

TABLE 4a: Bone Effects Associated with Bone Fluoride Content

TABLE 4b: Maximum Reported Fluoride Bone Concentrations in Humans Living in  $\leq 1.9$  ppm areas

5. Bone damage in relation to Urine Fluoride Content

TABLE 5a: Bone Effects Associated with Urine Fluoride Content

TABLE 5b: Urine Fluoride Levels in Fluoridated (1 ppm) Areas

6. Bone damage in relation to Duration of Exposure

TABLE 6. Variations in Individual Susceptibility to Skeletal Fluorosis: Duration of Exposure which Produces the Disease

7. Relationship between Water Fluoride & Serum Fluoride in Rats

TABLE 7: The relationship of Water Fluoride Concentration to Serum Fluoride Concentration in Rats

8. References

**TABLE 1: Bone & Teeth Effects Associated with Water Fluoride Content**

Water F Content	Effect	Study
0.6 ppm	Skeletal fluorosis in India	Teotia 1984 (cited in Susheela 1996)
1.0 ppm	20-80% of children (average = 48%) with very mild/mild dental fluorosis (mineralization defects of tooth enamel).	Heller 1997; Levy 1999; Locker 1999; McDonagh 2000
1.0 ppm	1.3% of children with moderate dental fluorosis	Heller 1997
1.0 ppm	Mineralization defects in cortical bone	Schlesinger 1956
1.0 ppm	Alterations in bone density	Kroger 1994, Arnold 1997, Phipps 2000
1.0 ppm	Increased hip Fractures in elderly	Mixed Epidemiology
1.0 ppm	Increased osteosarcoma (Bone Cancer)	Mixed Epidemiology
1.2-1.4 ppm	Skeletal fluorosis in India & China	Singh 1961; Jolly 1970; Siddiqui 1970; Xu 1997; Choubisa 2001; Bo 2003
1.5 ppm+	Mineralization defects of bone	Arnala 1985
1.5 ppm+	Bone fracture rates increased with increasing severity of dental fluorosis	Alarcon-Herrera 2001
1.5 ppm+	Doubling of hip fractures vs 1 ppm areas (not statistically significant)	Li 2001
1.7-2.0 ppm	Skeletal fluorosis in adults with kidney disease (US)	Johnson 1979
1.7-2.6 ppm	Skeletal fluorosis in teenagers with kidney disease (US)	Juncos & Donadio 1972
1.8-2.2 ppm	8% of children with moderate dental fluorosis; 5% with severe dental fluorosis	PHS 1991; NRC 1993
2.2-3.5 ppm	Crippling skeletal fluorosis (US)	Sauerbrunn 1965
3.8 ppm	Reduced cortical bone density	Phipps 1990
4.0 ppm	>30% of children with moderate/severe dental fluorosis	Dean 1942; NRC 1993
4.0 ppm	Bone F concentrations averaging 6,100-6,400 ppm in adults	Zipkin 1958, Gordon & Corbin 1992
4.0 ppm	Reduced bone mass + increased fractures	Sowers 1991
4.3 ppm+	Tripling of hip fractures vs 1ppm areas	Li 2001

**RELEVANCE TO CURRENT DRINKING WATER STANDARDS:**

Red indicates effects that have been observed at the current "Optimum" Fluoride level (1 ppm)

Blue indicates effects that have been observed below the current Secondary Maximum Contaminant Level (2 ppm).

Black indicates effects that have been observed at or below the current Maximum Contaminant Level (4 ppm)

<b>TABLE 2: Bone Effects Associated with Daily Doses of Fluoride</b>		
Dose of Fluoride	Bone Effect	Study
1.5 mg/day	Suggested maximum intake for kidney patients (to prevent skeletal fluorosis)	NIPHEP 1989
2-8 mg/day	Radiological evidence of skeletal fluorosis	Singh & Jolly 1970
2.5+ mg/day	Bone damage in children with calcium deficiency	Teotia 1998
5 mg/day	Recommended maximum intake to prevent skeletal fluorosis	NIPHEP 1989
6 mg/day	Suggestive evidence of adverse effects on human skeleton	WHO 2002
6 -9 mg/day	Suspected pre-clinical fluorosis marked by arthritic pain	Cook 1971
9.4 mg/day	Skeletal fluorosis	Bo 2003
9.6 mg/day	Skeletal fluorosis (mild to severe)	Teotia 1998
10 mg/day	Skeletal fluorosis	NRC 1993
10 mg/day	Skeletal fluorosis	IOM 1997
10-25 mg/day	Crippling Skeletal fluorosis	Hodge 1979
12 mg/day	Crippling Skeletal fluorosis	Cao 2003
14 mg/day*	Skeletal fluorosis	Liteplo 1994
14 mg/day	Clear adverse effects on human skeleton	WHO 2002
20+ mg/day*	Crippling skeletal fluorosis (retained dose = 12 mg/day)	Roholm 1937; see also Brun 1941
21-25 mg/day	Bone fractures in short term clinical trials (5 months to 4 years)	Inkovaara 1975; Gerster 1983; Bayley 1990; Hedlund 1990; Orcel 1990; Gutteridge 2002.
<b>RELEVANCE TO CURRENT DRINKING WATER STANDARDS:</b>		
Red indicates doses known to occur in 1 ppm areas (Cook 1971; PHS 1991; Mansfield 1999)		
Blue indicates doses known to occur in 4 ppm areas (EPA Water Consumption Data)		
Black indicates doses which would be reached by people drinking 5 liters of water/day in 4 ppm areas + other sources of F exposure.		
* Dose based on 70 kg adult.		

**TABLE 3a: Average Serum Fluoride Levels Reported in Human Skeletal Fluorosis**

Study	Serum F (umol/L)	Serum F (ppb)
Susheela 1981	25.3	480
Bo 2003	17.2	326
Barot 1998	14.6	278
Susheela 1996	12.6	240
Jin 2003*	10.5-12.1*	200-230*
Singla 1976	8.8	166
Li 1986	6.6	125
Li 1990	6.2	118
Yildiz 2003	5.8	110
Savas 2001	5.3	100

**RELEVANCE TO CURRENT DRINKING WATER STANDARDS:**

Red indicates serum F levels detected in people without kidney disease in 1 ppm areas (see Table 3c).

Blue indicates serum F levels detected in people with kidney disease in 1 ppm areas (see Table 3c).

Black indicates serum F levels detected in people with kidney disease in  $\leq 1.9$  ppm areas (see Table 3c).

**NOTE:** In 1979, Johnson & Jowsey of the Mayo Clinic, recommended that people with serum fluoride levels in excess of 5 umol/L reduce their fluoride exposure in order to prevent skeletal fluorosis. To quote:

“It would seem prudent to monitor the fluoride intake of patients with renal failure living in high fluoride areas. The serum concentration may indicate whether the patient should be advised to drink low fluoride water and will provide a check regarding compliance. Tentatively, a shift to low fluoride water should be made before the serum fluoride concentration reaches 5 umol/L, since evidence of (skeletal) fluorosis has been reported when the average serum concentrations of fluoride are 8 umol/L.”

As can be seen in Table 3c, even people without kidney disease have been found to have in excess of 5 umol/L in their blood in fluoridated (1 ppm) areas.

\* Children with severe dental fluorosis in a severe endemic fluorosis area. The skeletal status was not investigated.

<b>TABLE 3b: Serum Fluoride Levels Causing Damage to Mineralized Tissues in Rats</b>			
Study	Serum F (umol/L)	Serum F (ppb)	Effect
Dunipace 1995	1.4	27	Evidence of bone defects indicative of skeletal fluorosis
Whitford 1984	1.5	29	Mineralization defects in tooth enamel (dental fluorosis)
Whitford 1982	3.3	63	Mineralization defects in tooth enamel (dental fluorosis)
Crenshaw 1985 (cited by DenBesten 1985)	5	95	Inhibition of enzymes in tooth enamel
DenBesten 2002	5-10	95-190	Reduction of enzyme activity in tooth enamel
Turner 1996	7.6	144	Mineralization defects in bone (increased osteoid volume)
NTP 1990	8.2	156	Increased osteosarcoma (bone cancer)
Dunipace 1998; Turner 2001	~9-10	171-190	Reduced Bone Strength
Turner 1996	9.5	181	Reduced Bone Strength
Robinson 1990	10.6	201	"Dramatic" effect on enamel cell activity
Dunipace 1995; Turner 1995	10.8	205	Reduced bone strength
Dunipace 1995	12.1	230	Bone defects indicative of skeletal fluorosis
<b>RELEVANCE TO CURRENT DRINKING WATER STANDARDS:</b>			
Red indicates serum F levels known to be equaled, or exceeded, by humans without kidney disease in 1 ppm areas (see Table 3c).			
Blue indicates serum F levels known to be equaled, or exceeded, by humans with kidney disease in 1 ppm areas (see Table 3c).			
Black indicates serum F levels known to be exceeded by humans with kidney disease in 1.9 ppm areas (see Table 3c).			
For information on the water fluoride levels producing these serum fluoride levels in the rat, see Table 7.			

**TABLE 3c: Maximum Serum Fluoride Levels in Humans  
Living in  $\leq 1.9$  ppm areas**

Study	Water F	Reported Kidney Disease?	Serum F ( $\mu\text{mol/L}$ )	Serum F (ppb)
Johnson 1979	1.9 ppm	Yes	14.1	268
Johnson 1979	1.7 ppm	Yes	12	228
Hanhijarvi 1975	1 ppm	Yes	11.6	220
Torra 1998	0.2 ppm	Yes	9.7	185
Waterhouse 1980	1 ppm	Yes	8.6	163
Warady 1989	0.5 ppm	Yes	7.9	150
Singer 1979	1 ppm	No	6.8	130
Parkins 1974	1 ppm	No	5.9	112
Taves 1968	1 ppm	Yes	5.1	97
Pak 1994	1 ppm	No	5-10	95-190
Hall 1972	1 ppm	No	2.9	55
Husdan 1976	1 ppm	No	2.9	55

**RELEVANCE TO HUMAN HEALTH:**

Red indicates serum F levels which equal or exceed the levels found in human skeletal fluorosis (5.3  $\mu\text{mol/L}$ ).

Blue indicates serum F levels which also equal the levels found to reduce the strength of animal bone (9-10  $\mu\text{mol/L}$ ).

Black indicates serum F levels which also exceed the estimated toxic threshold in short-term human clinical trials (10  $\mu\text{mol/L}$ ).

**TABLE 4a: Bone Effects Associated with Bone Fluoride Content (BFC)**

BFC	Effect	Study
2,000-4,000 ppm	Possible bone fluorosis	Baud 1978
2,400 ppm	Impaired collagen synthesis (rats)	Uslu 1983
2,500 ppm	Reduced bone strength & damage to mineral/collagen composite (minipigs)	Lafage 1995, Fratzl 1996
2,876 ppm	Reduced bone strength (pigs)	Mosekilde 1987
3,300 ppm	Reduced bone quality (rats)	Sogaard 1995
3,400 ppm	Mineralization defects in humans with kidney disease	Ng 2004
3,500 ppm	First distinct histological and radiological changes in bones, with accompanying rheumatic pains in some humans	Franke 1975
3,800 ppm	Average in study reporting increased stress fractures (humans)	Orcel 1990
4,000 ppm	Diagnostic confirmation of bone fluorosis (humans)	Baud 1978
4,500 ppm	Reduced bone strength (animals)	Turner 1993
4,570 ppm	Mineralization defects (humans)	Boivin 1993
6,000 ppm	Clinical Phase 1 of skeletal fluorosis (humans)	PHS 1991
6,000 ppm	Mineralization defects (humans)	Ringe 1995
6,100 ppm	Advanced, crippling skeletal fluorosis in US (human)	Sauerbrunn 1965
6,000-7,000 ppm	Estimated toxic threshold, abnormal bone structure and mineralization defects (humans)	Zerwekh, Pak & Antich 1996

**RELEVANCE TO CURRENT DRINKING WATER STANDARDS:**

Red indicates bone concentrations within the range commonly found in  $\leq 1$  ppm areas (see Table 4b).

Blue indicates bone concentrations reported, but less frequently, in  $\leq 1$  ppm areas (see Table 4b).

Black indicates bone concentrations which are the *average* concentrations found in adults at 4 ppm (Zipkin 1958; Gordin & Corbin 1992)

**TABLE 4b: Maximum Fluoride Bone Concentrations in Humans Living in  $\leq 1.9$  ppm areas**

Study	Water F	Type of Bone	Reported Kidney Disease?	Fluoride Concentration (ppm ashed)*
Johnson 1979	1.9 ppm	iliac crest	Yes	11,180**
Jackson 1958	<0.5 ppm	rib	No	6,600*
Sogaard 1994	$\leq 0.2$ ppm	iliac crest	No	6,500
Kaye 1960		vertebrae	Yes	5,100
Hefti 1981	0.8-1.0 ppm	trabecular	Yes	4,810*
Jackson 1958	0.8-1.2 ppm	rib	No	4,563*
Alhava 1980	1 ppm	trabecular	No	4,140
Zipkin 1958	1 ppm	vertebrae	No	4,022
Richards 1994	< 0.2 ppm	iliac crest	No	4,000
Arnala 1985	1 ppm	trabecular	Yes	3,890
Stein 1980		vertebrae	No	3,720
Eble 1992	<0.2 – 1.0 ppm	trabecular & cortical combined	No	3,708
Ng 2004	1 ppm	iliac crest	Yes	3,400¶
Glock 1941	<0.5 ppm	rib	No	3,100
Huraib 1993	$\leq 1.0$ ppm	3,042¶	Yes	3,042¶
Kuo 1974	~ 0.2 ppm	rib	No	2,743

**RELEVANCE TO HUMAN HEALTH:**

Red indicates bone levels which exceed the levels found to reduce the strength of animal bone (Mosekilde 1987; Lafage 1995; Sogaard 1995).

Blue indicates bone levels associated with the pre-clinical phase of skeletal fluorosis according to the US Public Health Service (1991).

Teal indicates bone levels associated with the clinical phase of fluorosis according to Baud (1978).

Black indicates bone levels associated with the clinical phase of skeletal fluorosis according to the US Public Health Service (1991).

\* Indicates data initially reported in terms of dry fat-free bone. This data has been converted to the estimated ash equivalent using the equation presented by Charen (1979).

\*\* Indicates data initially reported in terms of the fluoride to calcium (F/Ca) ratio. This data has been converted to its estimated ash equivalent using the ratios provided by Taves (1970).

¶ - Indicates a study where no maximum bone concentration was given, just the average concentration. Based on the typical difference between the average and maximum bone concentrations for fluoride, it is probable that the maximum was 2,000 ppm+ greater than the reported average.

**Table 5a: Bone Effects Associated with Urine Fluoride Content**

Study	Effect	Urine F ppm (Range)	Urine F ppm (Average)
Brun 1941	Skeletal fluorosis	2.4-43.4	16.1
Singh 1961	Skeletal fluorosis	1.8-25.5	7.1
Cao 2003	Skeletal fluorosis	1.4-10.7	5.7
Derryberry 1963	Skeletal changes	2.2-8.9	5.2
Yildiz 2003	Skeletal fluorosis	N/A	4.2
Susheela 1996	Skeletal fluorosis	N/A	3.5
Pinet 1968	Skeletal fluorosis	0.5-12	3
Jin 2003	Severe Dental fluorosis	N/A	2.7-3.1
Bo 2003	Skeletal fluorosis	N/A	2.36
Savas 2001	Skeletal fluorosis	N/A	1.96

**RELEVANCE TO CURRENT DRINKING WATER STANDARDS:**

Red indicates a urine fluoride level known to occur in people living in  $\leq 1$  ppm areas (Mansfield 1999; see Table 5b).

**Table 5b: Urine Fluoride Levels in Fluoridated (1 ppm) Areas\***

Urine F (ppm)	West Midlands, UK No. (percent)	East Midlands, UK No. (percent)
< 0.3	4 (1.5)	4 (4.5)
0.3 < 0.7	30 (11.5)	20 (22.7)
0.7 < 1.0	60 (23.0)	11 (12.5)
1.0 < 1.3	49 (18.8)	22 (25.0)
1.3 < 1.7	31 (11.9)	10 (11.4)
1.7 < 2.0	28 (10.7)	5 (5.7)
2.0 < 2.3	25 (9.6)	5 (5.7)
2.3 < 2.7	8 (3.1)	4 (4.5)
2.7 < 3.0	9 (3.4)	2 (2.3)
3.0 < 3.3	4 (1.5)	1 (1.1)
3.3 < 3.7	4 (1.5)	1 (1.1)
3.7 < 4.0	4 (1.5)	2 (2.3)
≥ 4.0	5 (1.9)	1 (1.1)
Total No.	261 (99.9)	88 (99.9)
Mean F	1.46	1.28
Median F	1.2	1.1

**RELEVANCE TO CURRENT DRINKING WATER STANDARDS:**

Red indicates urine fluoride levels found in some people with skeletal fluorosis (see Table 5a).

\* Table reproduced from Mansfield (1999) .

<b>Table 6: Variations in Individual Susceptibility to Skeletal Fluorosis: Duration of Exposure which Produces the Disease</b>				
Study	Phase of Skeletal Fluorosis	Average Exposure (years)	Shortest Exposure (years)	Longest Exposure (years)
Roholm 1937	No Changes	8	2.8	24
Roholm 1937	Clinical Phase 1	9.3	2.4	33.8
Roholm 1937	Clinical Phase 2	9.7	4.8	28.9
Roholm 1937	Clinical Phase 3	21.1	11.2	31.2
Franke 1975	Vague Symptoms	10.71	2	25
Franke 1975	Stage 0-1	12.15	5	33
Franke 1975	Clinical Phase 1	15.7	8	38
Franke 1975	Clinical Phase 2	17.6	11	21
Franke 1975	Clinical Phase 3	19.5	19	20
Runge 1989	No Changes	19.9	5	35
Runge 1989	Vague Symptoms	19.2	10	37
Runge 1989	Stage 0-1	22.6	10	30
Runge 1989	Clinical Phase 1	21.1	10	43
Runge 1989	Clinical Phase 1-2	21.1	10	33
Runge 1989	Clinical Phase 2	17.5	16	19
Runge 1989	Clinical Phase 2-3	21.3	15	26
<b>RELEVANCE TO FLUORIDE SAFETY REGULATIONS:</b>				
<p>This data highlights the <u>wide range of individual susceptibility</u> to fluoride exposure. As can be seen, some people may develop skeletal fluorosis after just 2 to 5 years of excess exposure, while others may not develop any fluorosis, even after 40 years of excess exposure. Such variation in individual susceptibility underscores the importance of incorporating adequate <u>margins of safety</u> in all fluoride safety standards. Reasons for variation in susceptibility include nutritional status (Massler &amp; Schour 1952; Marier 1977; Teotia 1998); genetics (Polzik 1993, 1994; Everett 2002); difference in acidity of stomach/blood/kidney (Franke 1975; Whitford 1990) and difference in kidney function (Arnala 1985; Torra 1998).</p>				

**TABLE 7: The Relationship of Water Fluoride to Serum Fluoride in Rats**

Water F	Serum F (umol/L)	Serum F (ppb)	Study
Baseline	0.3	5	Dunipace 1995
Baseline	0.5	9	Turner 1996
5 ppm	1	19	Turner 1996
5 ppm	~1.0	~19	Dunipace 1998
5 ppm	1.4	27	Dunipace 1995
7 ppm	2	38	Buzalaf 2002
10 ppm	3	57	Whitford 1984
11.4 ppm	4.7	89	NTP 1990
14 ppm	3.3	63	Buzalaf 2002
15 ppm	~2.6	50	Dunipace 1998
15 ppm	3.3	62.7	Turner 1996
15 ppm	3.9	74	Dunipace 1995
25 ppm	~6.5-7	124-133	Whitford 1984
28 ppm	3.6	69	Buzalaf 2002
45.4 ppm	3.4	65	NTP 1990
47.5 ppm	~7	~133	Taves & Guy 1979
50 ppm	~9-10	~171-190	Dunipace 1998
50 ppm	9.5	181	Turner 1996
50 ppm	10.8	205	Dunipace 1995
56 ppm	9	171	Buzalaf 2002
60 ppm	~12-13	~228-247	Whitford 1984
75 ppm	~7	~133	DenBesten 1984
79.5 ppm	8.2	156	NTP 1990
95 ppm	~14	~266	Taves & Guy 1979
100 ppm	11.6	220	Buzalaf 2002
100 ppm	~11.6	~220	DenBesten 1984
150 ppm	17.9		DenBesten 1984

**RELEVANCE TO CURRENT DRINKING WATER STANDARDS:**

Red indicates serum F levels found in people without kidney disease in 1 ppm areas (see Table 3c).

Blue indicates serum F levels found in people with kidney disease in 1 ppm areas (see Table 3c).

Black indicates serum F levels known to be exceeded by people with kidney disease in 1.7-2.0 ppm areas (see Table 3c).

**SUMMARY:** As can be seen, rat studies using  $\leq 50$  ppm F in the water (without excess F in the food) produce serum fluoride levels experienced by a portion of the human population drinking water with 1 ppm fluoride.

~ Denotes an estimate of serum F based on data provided in graph form.

## 8. REFERENCES:

Alarcon-Herrera MT, et al. (2001). Well water fluoride, dental fluorosis, bone fractures in the Guadiana Valley of Mexico. *Fluoride* 34(2): 139-149.

Alhava EM, et al. (1980). The effect of drinking water fluoridation on the fluoride content, strength and mineral density of human bone. *Acta Orthopaedica Scandinavica* 51: 413-420.

Arnala I, et al. (1985). Effects of fluoride on bone in Finland. Histomorphometry of cadaver bone from low and high fluoride areas. *Acta Orthopaedica Scandinavica* 56(2):161-6.

Arnold CM, et al. (1997). The effect of water fluoridation on the bone mineral density of young women. *Canadian Journal of Public Health* 88(6):388-91.

Barot VV. (1998). Occurrence of endemic fluorosis in human population of North Gujarat, India: human health risk. *Bulletin of Environmental Contamination and Toxicology* 61: 303-10.

Baud CA, et al. (1978). Value of the bone biopsy in the diagnosis of industrial fluorosis. *Virchows Archiv A. Pathological Anatomy and Histology* 380(4): 283-97.

Bayley TA, et al. (1990). Fluoride-induced fractures: relation to osteogenic effect. *Journal of Bone and Mineral Research* 5(Suppl 1):S217-22.

Bo Z, et al. (2003). Distribution and risk assessment of fluoride in drinking water in the West Plain region of Jilin Province, China. *Environmental Geochemistry and Health* 25: 421-431.

Boivin G, et al. (1993). Relationship between bone fluoride content and histological evidence of calcification defects in osteoporotic women treated long term with sodium fluoride. *Osteoporosis International* 3(4):204-8.

Brun G, Buchwald H, Roholm K. (1941). [The excretion of fluorine in the urine of cryolite workers with chronic fluorine poisoning]. *Acta Medica Scandinavica* 106: 261-273.

Buzalaf MA, et al. (2002). Correlation between plasma and nail fluoride concentrations in rats given different levels of fluoride in water. *Fluoride* 35: 185-192.

Cao J, et al. (2003). Brick tea fluoride as a main source of adult fluorosis. *Food and Chemical Toxicology* 41: 535-42.

Charen J, et al. (1979). Bone fluoride concentrations associated with fluoridated drinking water. *Calcified Tissue International* 27(2):95-9.

Choubisa SL, et al. (2001). Endemic fluorosis in Rajasthan. *Indian Journal of Environmental Health* 43: 177-89.

Cook HA. (1971). Fluoride studies in a patient with arthritis. *Lancet* October 9: 817.

Denbesten PK, et al. (1985). Changes in the fluoride-induced modulation of maturation stage ameloblasts of rats. *Journal of Dental Research* 64: 1365-70.

DenBesten PK, Crenshaw MA. (1984). The effects of chronic high fluoride levels on forming enamel in the rat. *Archives of Oral Biology* 29: 675-9.

Derryberry OM, et al. (1963). Fluoride exposure and worker health. *Archives of Environmental Health* 6: 65-73.

Dunipace AJ, et al. (1998). Chronic fluoride exposure does not cause detrimental, extraskelatal effects in nutritionally deficient rats. *Journal of Nutrition* 128: 1392-400.

Dunipace AJ, et al. (1995). Effect of aging on animal response to chronic fluoride exposure. *Journal of Dental Research* 74: 358-68.

Eble DM, et al. (1992). Fluoride concentrations in human and rat bone. *Journal of Public Health Dentistry* 52: 288-291.

Environmental Protection Agency [EPA]. (Online). Drinking Water and Health Advisories Estimated Per Capita Water Ingestion in the United States  
<http://www.epa.gov/waterscience/drinking/percapita/>

Everett ET, et al. (2002). Dental fluorosis: variability among different inbred mouse strains. *Journal of Dental Research* 81: 794-8.

Franke J, et al. (1975). Industrial fluorosis. *Fluoride* 8(2): 61-83.

Fratzl P, et al. (1996). Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle X-ray scattering and backscattered electron imaging study. *Journal of Bone and Mineral Research* 11: 248-53.

Gerster JC, et al. (1983). Bilateral fractures of femoral neck in patients with moderate renal failure receiving fluoride for spinal osteoporosis. *British Medical Journal (Clin Res Ed)* 287(6394):723-5.

Glock GE, et al. (1941). The retention and elimination of fluoride in bones. *Biochemical Journal* 35: 1235-1239.

Gordon SL, Corbin SB. (1992). Summary of Workshop on Drinking Water Fluoride Influence on Hip Fracture on Bone Health. *Osteoporosis International* 2: 109-117.

Gutteridge DH, et al. (2002). A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. *Osteoporosis International* 13(2):158-70.

- Hall LL, et al. (1972). Direct potentiometric determination of total ionic fluoride in biological fluids. *Clinical Chemistry* 18(: 1455-8.
- Hanhijarvi H. (1975). Inorganic plasma fluoride concentrations and its renal excretion in certain physiological and pathological conditions in man. *Fluoride* 8: 198-207.
- Hedlund LR, Gallagher JC. (1989). Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. *Journal of Bone and Mineral Research* 4:223-5.
- Hefti A, Marthaler TM. (1981). Bone fluoride concentrations after 16 years of drinking water fluoridation. *Caries Research* 15(1):85-9.
- Heller KE, et al. (1997). Dental Caries and Dental Fluorosis at Varying Water Fluoride Concentrations. *Journal of Public Health Dentistry* 57: 136-143.
- Hodge HC. (1979). The Safety of Fluoride Tablets or Drops. In: Johansen E, Taves DR, Olsen TO, Eds. Continuing Evaluation of the Use of Fluorides. AAAS Selected Symposium. Westview Press, Boulder, Colorado. pp. 253-274.
- Huraib S, et al. (1993). Pattern of renal osteodystrophy in haemodialysis patients in Saudi Arabia. *Nephrology Dialysis Transplantation* 8: 603-8.
- Husdan H, et al. (1976). Serum ionic fluoride: normal range and relationship to age and sex. *Clinical Chemistry* 22: 1884-8.
- Inkovaara J, et al. (1975). Prophylactic fluoride treatment and aged bones. *British Medical Journal* 3(5975):73-4.
- Institute of Medicine [IOM]. (1999). Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. National Academy Press.
- Jackson D, Weidman SM. (1958). Fluorine in human bone related to age and the water supply of different regions. *Journal of Pathological Bacteriology* 76: 451-459.
- Jin C, et al. (2003). Prevention and control of brick-tea type fluorosis—a 3-year observation in Dangxiong, Tibet. *Ecotoxicology and Environmental Safety* 56: 222-7.
- Johnson W, et al. (1979). Fluoridation and bone disease in renal patients. In: Johansen E, Taves DR, Olsen TO, Eds. Continuing Evaluation of the Use of Fluorides. AAAS Selected Symposium. Westview Press, Boulder, Colorado. pp. 275-293.
- Jolly SS. (1970). Hydric fluorosis in Punjab (India). In: Vischer TL. Fluoride in Medicine. Hans Huber: Switzerland. pp. 106-121.

- Juncos LI, Donadio JV Jr. (1972). Renal failure and fluorosis. *Journal of the American Medical Association* 222: 783-5.
- Kaye M, et al. (1960). Bone disease in chronic renal failure with particular reference to osteosclerosis. *Medicine* 39: 157-190.
- Kroger H, et al. (1994). The effect of fluoridated drinking water on axial bone mineral density—a population-based study. *Bone Mineral* 27(1):33-41.
- Kuo HC, Stamm JW. (1974). Fluoride levels in human rib bone: a preliminary study. *Canadian Journal of Public Health* 65(5):359-61.
- Lafage MH, et al. (1995). Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study. *Journal of Clinical Investigation* 95(5):2127-33.
- Levy SM, Guha-Chowdhury N. (1999). Total fluoride intake and implications for dietary fluoride supplementation. *Journal of Public Health Dentistry* 59: 211-23.
- Li C, Ke X. (1990). Ionic, Nonionic, and Total Fluoride in Human Serum. *Fluoride* 23: 164-170.
- Li CS, et al. (1986). Relationships Between Ionic Fluoride, Total Fluoride, Calcium, Phosphorus, and Magnesium in Serum of Fluorosis Patients. *Fluoride* 19: 184-187.
- Li Y, et al. (2001). Effect of long-term exposure to fluoride in drinking water on risks of bone fractures. *Journal of Bone and Mineral Research* 16(5):932-9.
- Liteplo RG, et al. (1994). Inorganic fluoride: Evaluation of risks to health from environmental exposure in Canada. *Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews* 12: 327-344.
- Mansfield P. (1999). The distribution of urinary fluoride concentration in the UK. *Fluoride* 32: 27-32.
- Marier J, Rose D. (1977). Environmental Fluoride. National Research Council of Canada. Associate Committee on Scientific Criteria for Environmental Quality. NRCC No. 16081. (Available online at: <http://www.fluorideaction.org/nrc-fluoride.htm> )
- Massler M, Schour I. (1952). Relation of endemic dental fluorosis to malnutrition. *Journal of the American Dental Association* 44: 156-165.
- McDonagh M, et al. (2000). A systematic review of public water fluoridation. Report 18, NHS [National Health Service] Centre for Reviews and Dissemination, University of York, York, UK.
- Mosekilde L, et al. (1987). Compressive strength, ash weight, and volume of vertebral trabecular bone in experimental fluorosis in pigs. *Calcified Tissue Research* 40: 318-322.

National Institute for Public Health and Environmental Protection [NIPHEP]. (1989). Integrated criteria document fluorides. Report No 758474010. The Netherlands.

National Research Council [NRC]. (1993). Health effects of ingested fluoride. Report of the Subcommittee on Health Effects of Ingested Fluoride. National Academy Press, Washington, DC.

National Toxicology Program [NTP] (1990). Toxicology and Carcinogenesis Studies of Sodium Fluoride in F344/N Rats and B6C3f1 Mice. Technical report Series No. 393. NIH Publ. No 91-2848. National Institute of Environmental Health Sciences, Research Triangle Park, N.C.

Ng AHM, et al. (2004). Association between fluoride, magnesium, aluminum and bone quality in renal osteodystrophy. *Bone* 34: 216-224.

Orcel P, et al. (1990). Stress fractures of the lower limbs in osteoporotic patients treated with fluoride. *Journal of Bone and Mineral Research* 5(Suppl 1): S191-4.

Parkins FM, et al. (1974). Relationships of human plasma fluoride and bone fluoride to age. *Calcified Tissue Research* 16: 335-8.

Pak CY, et al. (1994). Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial. *Annals of Internal Medicine* 120(8):625-32.

Pak CY. (1989). Fluoride and osteoporosis. *Proceedings of the Society for Experimental Biology and Medicine* 191: 278-86.

Phipps KR, et al. (2000). Community water fluoridation, bone mineral density and fractures: prospective study of effects in older women. *British Medical Journal* 321: 860-4.

Phipps KR, Burt BA. (1990). Water-borne fluoride and cortical bone mass: A comparison of two communities. *Journal of Dental Research* 69: 1256-1260.

Pinet A, Pinet F. (1968). Endemic fluorosis in the Sahara. *Fluoride* 1: 86-93.

Public Health Service [PHS]. (1991). Review of fluoride: benefits and risks. Report of the Ad Hoc Subcommittee on Fluoride. Washington, DC.

Polzik EV, et al. (1994). A method for estimating individual predisposition to occupational fluorosis. *Fluoride* 27: 194-200.

Polzik EV, et al. (1993). Factors of individual predisposition to occupational fluorosis. *Fluoride* 26: 257-262.

Richards A, et al. (1994). Normal age-related changes in fluoride content of vertebral trabecular bone - Relation to bone quality. *Bone* 15: 21-26.

Ringe JD, Meunier PJ. (1995). What is the future for fluoride in the treatment of osteoporosis? *Osteoporosis International* 5: 71-4.

Robinson C, Kirkham J. (1990). The effect of fluoride on the developing mineralized tissues. *Journal of Dental Research* 69(Spec Issue): 685-91.

Roholm K. (1937). Fluoride intoxication: a clinical-hygienic study with a review of the literature and some experimental investigations. London: H.K. Lewis Ltd.

Runge H, Franke J. (1989). Radiological modification of the skeletal system among aluminum smelter workers: A 15-year retrospective study. *Fluoride* 22: 157-164.

Sauerbrunn BJ, et al. (1965). Chronic fluoride intoxication with fluorotic radiculomyelopathy. *Annals of Internal Medicine* 63: 1074-1078.

Savas S, et al. (2001). Endemic fluorosis in Turkish patients: relationship with knee osteoarthritis. *Rheumatology International* 21: 30-5.

Schlesinger ER, et al. (1956). Newburgh-Kingston caries-fluorine study XIII. Pediatric findings after ten years. *Journal of the American Dental Association* 52: 296.

Siddiqui AH. (1970). Neurological complications of skeletal fluorosis with special reference to lesions in the cervical region. *Fluoride* 3: 91-96.

Siddiqui AH. (1955). Fluorosis in Nalgonda District, Hyderabad-Deccan. *British Medical Journal* 2: 1408-1413.

Singer L, Ophaug RH. (1979). Concentrations of ionic, total, and bound fluoride in plasma. *Clinical Chemistry* 25: 523-5.

Singh A, Jolly SS. (1970). Fluorides and Human Health. World Health Organization. pp 239-240.

Singh A, et al. (1961). Skeletal fluorosis and its neurological complications. *Lancet* 1: 197-200.

Singla VP, et al. (1976). Symposium on the non-skeletal phase of chronic fluorosis: The Kidneys. *Fluoride* 9: 33-35.

Sogaard CH, et al. (1995). Effects of fluoride on rat vertebral body biomechanical competence and bone mass. *Bone* 16(1): 163-9.

Sogaard CH, et al. (1994). Marked decrease in trabecular bone quality after five years of sodium fluoride therapy--assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. *Bone* 15(4): 393-99.

Sowers M, et al. (1991). A prospective study of bone mineral content and fracture in communities with differential fluoride exposure. *American Journal of Epidemiology* 133: 649-660.

Stein ID, Granik G. (1980). Human vertebral bone: Relation of strength, porosity, and mineralization to fluoride content. *Calcified Tissue International* 32: 189-194.

Susheela AK, Jethanandani P. (1996). Circulating testosterone levels in skeletal fluorosis patients. *Journal of Toxicology: Clinical Toxicology* 34: 183-9.

Susheela AK, et al. (1981). Chemical Profile of Human Serum in Fluoride Toxicity and Fluorosis: 1. Total Protein-Bound Carbohydrates, Seromucoid and Fluoride Levels. *Fluoride* 14: 150-154.

Taves DR, Guy WS. (1979). Distribution of fluoride among body compartments. In: Johansen E, Taves DR, Olsen TO, Eds. Continuing Evaluation of the Use of Fluorides. AAAS Selected Symposium. Westview Press, Boulder, Colorado. pp. 159-185.

Taves DR. (1970). New approach to the treatment of bone disease with fluoride. *Federation Proceedings* 29: 1185-1187.

Taves DR, et al. (1968). Hemodialysis with fluoridated dialysate. *Transactions of the American Society for Artificial Internal Organs* 14: 412-4.

Teotia SPS, Teotia SP, Singh KP. (1998). Endemic chronic fluoride toxicity and dietary calcium deficiency interaction syndromes of metabolic bone disease and deformities in India: year 2000. *Indian Journal of Pediatrics* 65: 371-381.

Torra M, et al. (1998). Serum and urine fluoride concentration: relationships to age, sex and renal function in a non-fluoridated population. *Science of the Total Environment* 220: 81-5.

Turner CH, et al. (2001). Combined effects of diets with reduced calcium and phosphate and increased fluoride intake on vertebral bone strength and histology in rats. *Calcified Tissue International* 69: 51-7.

Turner CH, et al. (1996). High fluoride intakes cause osteomalacia and diminished bone strength in rats with renal deficiency. *Bone* 19(6):595-601.

Turner CH, et al. (1995). Fluoride reduces bone strength in older rats. *Journal of Dental Research* 74(8):1475-81.

Turner CH, Dunipace AJ. (1993). On fluoride and bone strength (letter). *Calcified Tissue International* 53: 289-290.

Uslu B. (1983). Effect of fluoride on collagen synthesis in the rat. *Research and Experimental Medicine* 182(1):7-12.

Warady BA, et al. (1989). Plasma fluoride concentration in infants receiving long-term peritoneal dialysis. *Journal of Pediatrics* 115: 436-9.

Waterhouse C, et al. (1980). Serum inorganic fluoride: changes related to previous fluoride intake, renal function and bone resorption. *Clinical Science* 58: 145-52.

Whitford GM. (1990). The physiological and toxicological characteristics of fluoride. *Journal of Dental Research* 69(Spec No): 539-49.

Whitford GM, Angmar-Mansson B. (1984). Enamel fluorosis related to plasma F levels in the rat. *Caries Research* 18: 25-32.

Whitford GM, Angmar-Mansson B. (1982). Plasma fluoride levels and enamel fluorosis in the rat. *Caries Research* 16: 334-9.

World Health Organization. (2002). Environmental Health Criteria 227: FLUORIDES. World Health Organization, Geneva.

Xu RQ, et al. (1997). Relations between environment and endemic fluorosis in Hohhot region, Inner Mongolia. *Fluoride* 30: 26-28.

Yildiz M, et al. (2003). Bone mineral density of the spine and femur in early postmenopausal Turkish women with endemic skeletal fluorosis. *Calcified Tissue International* 72: 689-93.

Zerwekh JE, Antich P, Pak CY. (1996). Fluoride and the FDA (letter). *Journal of Bone and Mineral Research* 11: 1370-1371.

Zipkin L, et al. (1958). Fluoride deposition in human bones after prolonged ingestion of fluoride in drinking water. *US Public Health Reports* 73:732-740.